The stock price of Organogenesis Holdings Inc (NASDAQ: ORGO) has surged by 2.09 when compared to previous closing price of 2.39, but the company has seen a 3.83% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-16 that CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th.
Is It Worth Investing in Organogenesis Holdings Inc (NASDAQ: ORGO) Right Now?
Organogenesis Holdings Inc (NASDAQ: ORGO) has a higher price-to-earnings ratio of 66.49x compared to its average ratio. ORGO has 36-month beta value of 1.63. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ORGO is 77.59M, and currently, short sellers hold a 10.72% ratio of that float. The average trading volume of ORGO on May 08, 2024 was 912.13K shares.
ORGO’s Market Performance
ORGO’s stock has seen a 3.83% increase for the week, with a -17.85% drop in the past month and a -28.86% fall in the past quarter. The volatility ratio for the week is 9.81%, and the volatility levels for the past 30 days are at 7.82% for Organogenesis Holdings Inc The simple moving average for the last 20 days is -9.91% for ORGO stock, with a simple moving average of -19.59% for the last 200 days.
Analysts’ Opinion of ORGO
Many brokerage firms have already submitted their reports for ORGO stocks, with Cantor Fitzgerald repeating the rating for ORGO by listing it as a “Overweight.” The predicted price for ORGO in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on February 07, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see ORGO reach a price target of $5. The rating they have provided for ORGO stocks is “Equal-Weight” according to the report published on June 15th, 2023.
BTIG Research gave a rating of “Buy” to ORGO, setting the target price at $10 in the report published on May 24th of the previous year.
ORGO Trading at -13.95% from the 50-Day Moving Average
After a stumble in the market that brought ORGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.14% of loss for the given period.
Volatility was left at 7.82%, however, over the last 30 days, the volatility rate increased by 9.81%, as shares sank -16.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.09% lower at present.
During the last 5 trading sessions, ORGO rose by +3.83%, which changed the moving average for the period of 200-days by -43.52% in comparison to the 20-day moving average, which settled at $2.68. In addition, Organogenesis Holdings Inc saw -40.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ORGO starting from ERANI ALBERT, who sale 17,972 shares at the price of $4.28 back on Jan 10 ’24. After this action, ERANI ALBERT now owns 59,007,134 shares of Organogenesis Holdings Inc, valued at $76,875 using the latest closing price.
ERANI ALBERT, the 10% Owner of Organogenesis Holdings Inc, sale 17,972 shares at $4.28 during a trade that took place back on Jan 10 ’24, which means that ERANI ALBERT is holding 59,007,134 shares at $76,875 based on the most recent closing price.
Stock Fundamentals for ORGO
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.74 for the gross margin
The net margin for Organogenesis Holdings Inc stands at 0.03. The total capital return value is set at 0.04. Equity return is now at value 1.82, with 1.09 for asset returns.
Based on Organogenesis Holdings Inc (ORGO), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 0.38. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is 11.12.
Currently, EBITDA for the company is 39.77 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 0.78. The receivables turnover for the company is 5.28for trailing twelve months and the total asset turnover is 0.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.80.
Conclusion
To put it simply, Organogenesis Holdings Inc (ORGO) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
